July 8, 2025
| Trial | AHEAD-MERIT (BNT113) |
|---|---|
| Cancer Type | Head & Neck Cancer |
| Hospital(s) | Belfast City Hospital |
| Information | An open-label Phase II randomized trial of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first line therapy in patients with unresectable recurrent, or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+) and expresses PD-L1 |
 |
Click Here to view Cancer Research UK trial summary |